Contains fulltext : 48830.pdf (publisher's version ) (Closed access)RATIONALE: The central cholinergic system is implicated in cognitive functioning. The dysfunction of this system is expressed in many diseases like Alzheimer's disease, dementia of Lewy body, Parkinson's disease and vascular dementia. In recent animal studies, it was found that selective cholinergic modulation affects visuospatial processes even more than memory function. OBJECTIVE: In the current study, we tried to replicate those findings. In order to investigate the acute effects of cholinergic drugs on memory and visuospatial functions, a selective anticholinergic drug, biperiden, was compared to a selective acetylcholinesterase-inhibiting drug, rivast...
Scopolamine has been used as a pharmacologic model for cognitive impairments in dementia and Alzheim...
OBJECTIVE: To assess the potential of anticholinergic drugs as a cause of non-degenerative mild cogn...
Background/Aims: The nature and extent of adverse cognitive effects due to the prescription of antic...
Contains fulltext : 55636.pdf (publisher's version ) (Closed access)Rationale The...
In the last 20 years a cholinergic dysfunction has been the major working hypothesis for the pharmac...
grantor: University of TorontoBackground. An increased pharmacological response to cholin...
Objective: Impairments of spatial and verbal memory are early and common symptoms in Alzheimer\u2019...
Although neurochemical reductions in cholinergic systems have been found to occur during aging, such...
Contains fulltext : 53257.pdf (publisher's version ) (Closed access)Ampakines act ...
Although the exact pathogenesis of Alzheimer’s disease (AD) remains unclear, the widespread loss of ...
OBJECTIVE: Age-associated cholinergic dysfunction may contribute to the cognitive decline observed d...
Objective: Age-associated cholinergic dysfunction may contribute to the cognitive decline observed d...
Scopolamine has been used as a pharmacologic model for cognitive impairments in dementia and Alzheim...
Contains fulltext : 55383.pdf (publisher's version ) (Closed access)Ampakines act ...
OBJECTIVE: Age-associated cholinergic dysfunction may contribute to the cognitive decline observed d...
Scopolamine has been used as a pharmacologic model for cognitive impairments in dementia and Alzheim...
OBJECTIVE: To assess the potential of anticholinergic drugs as a cause of non-degenerative mild cogn...
Background/Aims: The nature and extent of adverse cognitive effects due to the prescription of antic...
Contains fulltext : 55636.pdf (publisher's version ) (Closed access)Rationale The...
In the last 20 years a cholinergic dysfunction has been the major working hypothesis for the pharmac...
grantor: University of TorontoBackground. An increased pharmacological response to cholin...
Objective: Impairments of spatial and verbal memory are early and common symptoms in Alzheimer\u2019...
Although neurochemical reductions in cholinergic systems have been found to occur during aging, such...
Contains fulltext : 53257.pdf (publisher's version ) (Closed access)Ampakines act ...
Although the exact pathogenesis of Alzheimer’s disease (AD) remains unclear, the widespread loss of ...
OBJECTIVE: Age-associated cholinergic dysfunction may contribute to the cognitive decline observed d...
Objective: Age-associated cholinergic dysfunction may contribute to the cognitive decline observed d...
Scopolamine has been used as a pharmacologic model for cognitive impairments in dementia and Alzheim...
Contains fulltext : 55383.pdf (publisher's version ) (Closed access)Ampakines act ...
OBJECTIVE: Age-associated cholinergic dysfunction may contribute to the cognitive decline observed d...
Scopolamine has been used as a pharmacologic model for cognitive impairments in dementia and Alzheim...
OBJECTIVE: To assess the potential of anticholinergic drugs as a cause of non-degenerative mild cogn...
Background/Aims: The nature and extent of adverse cognitive effects due to the prescription of antic...